Author: Newsdesk

NORTH BAY, Ontario, Nov. 25, 2020 (GLOBE NEWSWIRE) — The third installment of Canada’s Rural & Remote Broadband Conference will be held this upcoming Friday, November 27, 2020. Conference Founder, Amedeo Bernardi stated, “The current pandemic is fundamentally changing where we work and our expectations for connectivity anywhere in Canada. It has also helped turn the tide and is making broadband into an essential public good as opposed to just a consumer good.”

The live sessions will include a wide range of topics spanning policy, advocacy and technical. Community and industry leaders will explore a range of issues including a retrospective look at the impacts of COVID-19 on rural networks and policies, discuss action items from the Internet Society’s recent North American Indigenous Summit, delineate the many gaps communities need to address so to secure improved broadband access, and funding models that do not solely rely on government grants. Attendees will be encouraged to participate in live Q&A with the speakers.

The “International Community Models – Lessons for Canada” panel includes speakers from The United Kingdom, Sweden, United States and Australia.

Additionally, our session “Reality Check – Putting LEO into Perspective” brings together leaders from Canada’s satellite industry to discuss the Canadian roadmap while sharing facts and dispelling some myths about Low Earth Orbit satellite technology.

Make sure to register now for this unique and timely event at www.bridgingthedigitaldivide.ca.

ABOUT THE EVENT
:

This is the third installment of the Canadian Rural and Remote Broadband Conference and continues to provide a tremendous information sharing forum for community leaders, rural advocates, service providers and government, especially as Canada tries to cope with the impacts of COVID-19.

This conference will be essential for anyone who wants to better understand rural and remote broadband challenges, engage with other stakeholders to learn about their experiences, and explore the options to collaborate so to deliver effective solutions.

Please click here for registration packages and details.

Thank you to the following sponsors for their support of this
important
event!

Calix – Founding Sponsor
Cartt.ca – Media Sponsor
Rogers, CENGN, IBI Consulting, NISC, Parry Sound Muskoka Community Network,
CCSA, CIRA, i-Valley, Red Oak Technologies, COS Systems, Telesat,
Canada Infrastructure Bank, Corning, KGPCo, Vianet, Internet Society, SatCan

For more information, please contact Amedeo Bernardi at [email protected].

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual fireside chats at the following investor conferences:

• Piper Sandler 32nd Annual Virtual Healthcare Conference on December 2 at 2:30 p.m. ET;
• Evercore ISI 3rd Annual HealthCONx on December 3 at 10:55 a.m. ET.

The fireside chats will be webcast live from GBT’s website at www.gbt.com in the Investors section. Replays of the webcast will be archived and available for one month following each event.

About Global Blood Therapeutics

Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601, the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact Information:

Steven Immergut (investors and media)
650-410-3258
[email protected]

 

WOBURN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) — Abpro Corporation today announced the expansion of its scientific advisory board with additions of infectious disease drug development leaders. The advisors join as the Company continues development of its neutralizing antibody therapeutic, ABP300, in clinical trials for treatment of SARS-CoV2 (COVID-19) infection.

“We are proud to have doctors George Hanna, M.D., Daniel Kuritzkes, M.D., and Steven Schnittman, M.D., join our scientific advisory board at such a critical time for our Company, and a pivotal moment during the ongoing COVID-19 pandemic,” said Ian Chan, chief executive officer of Abpro. “Given the promise of ABP300 and its demonstrated ability to safely and effectively neutralize the SARS-CoV2 virus in non-human primate models, we are determined to advance ABP300 through clinical studies with the hope of delivering it to patients in need as quickly and diligently as possible. The proven track records and unquestioned expertise of these new, esteemed members of our advisory board will be invaluable in our Company’s push to accomplish this mission, and we warmly welcome them to our team.”

Dr. George Hanna is a physician-scientist, board-certified in internal medicine and infectious diseases, with 20 years of academic research and biopharmaceutical experience in early and late-stage clinical drug development and scientific and medical affairs, spanning multiple disease areas with a focus in infectious diseases. Dr. Hanna was most recently the Vice President and Therapeutic Area Head of Infectious Diseases, Global Clinical Development at Merck. Prior to his time at Merck, Dr. Hanna held positions of ascending responsibility and impact within the biotechnology and pharmaceutical industry focused on clinical development of therapeutics for the treatment of virological and infectious diseases, including Global Project Head, Antiviral Global Project Team at Abbott Laboratories, Director of Clinical Discovery, Virology at Bristol Myers-Squibb. He received his B.S in Biology from Harvard University, and his medical degree from the Baylor College of Medicine.

Dr. Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women’s Hospital in Boston, Massachusetts. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has been a member of several editorial boards and serves an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School.

Dr. Steven Schnittman brings to Abpro 35 years of experience in innovative drug development, concentrating on Virology, with special expertise on establishing and serving on data and safety monitoring review committees as well as preparing for FDA Advisory Committees/EU Oral Hearings. Dr. Schnittman is currently a faculty appointment at the Yale University School of Medicine and Physician at West Haven VA Medical Center, and is a consultant focused on solving critical issues and questions of clinical development planning that supports global regulatory approvals and commercialization. Prior to independent consulting, Dr. Schnittman served in various roles of increasing responsibility at Bristol Myers-Squibb, most recently as the Vice President of Global Clinical Research, with accomplishments highlighted by the submissions of over 10 new drug or supplemental new drug applications that led to eventual approvals by various public regulatory agencies worldwide. Dr. Steven Schnittman earned his B.S. in Biology and Economics from New York University, and his medical degree from the New York University School of Medicine.

About ABP 300

ABP 300 is a human neutralizing monoclonal antibody therapy against COVID-19 that was created using the latest technologies available for antibody discovery. ABP 300 disrupts the interaction of the viral receptor binding domain (RBD) with host angiotensin-converting enzyme 2 (ACE2) receptor and has shown neutralizing efficacy in vivo against COVID-19 by blocking viral entry into cells. ABP300 recently completed a Phase 1 dose escalation study in human subjects. Recent preclinical data has also been published in Nature Communications.

About Abpro

Abpro Corporation is a clinical stage biotechnology company located in Woburn, Massachusetts. The Company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro’s DiversImmune™ platform has been used successfully against 300 traditionally difficult targets. The Company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas. For more information, please visit www.abpro.com.

Media Contact

Michael Tattory
LifeSci Communications
1 (646) 751-4362
[email protected]

TORONTO, Nov. 25, 2020 (GLOBE NEWSWIRE) — YANGAROO Inc. (“Yangaroo”, “Company”), (TSX-V: YOO, OTCBB: YOOIF), the software leader in work-flow management and media distribution solutions, today announced its results for the quarter ended September 30, 2020. The full text of the Financial Statements and Management Discussion & Analysis is available at www.yangaroo.com and at www.sedar.com. Please note that all currency in this press release is denominated in Canadian dollars.

Consolidated revenue for the third quarter of 2020 was $1,921,312 compared to $1,959,312 and $1,586,695 in the third quarter of 2019 and second quarter of 2020, respectively. The Company generated normalized EBITDA of $502,299, inclusive of government wage subsidy payments, during the quarter ended September 30, 2020, in comparison to a normalized EBITDA of $255,834 in the prior year quarter ended September 30, 2019 and normalized EBITDA of $118,700 in the second quarter of 2020 ended June 30, 2020. The increase in revenue and normalized EBITDA in Q3’2020 is primarily attributed to increased Advertising and Awards revenue resulting from a recovery in customer demand for the use of our workflow platform. The second quarter of 2020 saw a significant advertising industry wide slump in volume of new advertising campaigns and total dollar spend which was attributed to the global COVID-19 pandemic. The third quarter of 2020 observed advertising volumes and total dollar spend recovering to pre-pandemic levels. Awards revenue was also significantly impacted in the first half of 2020, and we saw a strong rebound in award show customers using our platform in the third quarter of 2020 resulting in significantly higher Awards revenues.

Music revenue continued to increase during these comparison periods and partially helped off-set any impact from COVID-19. The Company continued to see strong demand for its Music platform in the form of recurring subscription revenues and on-demand platform usage from independent music artists and music labels. Finally, government wage subsidies and cost management initiatives contributed to a gain in normalized EBITDA earnings during the quarter.

“The third quarter of 2020 saw a swift recovery in the demand for our platform from our advertising and awards customers as the economy continued to rebound from the initial impact of COVID-19 in the first half of 2020,” stated recently appointed Interim CEO of Yangaroo, Grant Schuetrumpf. “We have seen signs of resumption in advertising campaigns across a broad spectrum of clients to pre-pandemic levels and we expect this recovery to continue through to the end of 2020. Awards division revenues increased significantly as many of our clients restarted their award shows from an initial deferral in Q1’ and Q2’2020, and we expect this trend to continue through to the end of 2020. Finally, our Music revenues have continued to be a bright spot for Yangaroo as independent music artists and music labels increased their usage of the platform resulting in 20% revenue growth quarter over prior-year quarter.”

Grant Schuetrumpf added, “We ended the third quarter with a strong recovery in revenue and demand for our platform and we expect this trend to continue through to the fourth quarter of 2020. Additionally, our balance sheet and cash position has never been stronger with over $2 million in cash and over $3 million in working capital on top of an undrawn $1 million revolving loan facility. We are very optimistic about the future prospects of our business and achieving our previously stated growth targets in 2021, which is in stark contrast to some of the outlook scenarios we were facing at the beginning of the pandemic. Finally, we continue to evaluate and be opportunistic with organic and non-organic growth initiatives.”

As at September 30, 2020, the Company has a cash position of $2.3 million and a working capital position of $3.1 million. The Company’s share buy-back program continues to be suspended and will continue to be evaluated on an on-going basis.

Summary of operating results:

	Three Months						Nine Months
	2020			2019			2020			2019
Revenue	$	1,921,312		$	1,959,865		$	5,880,774		$	5,580,655
Gross Margin		93.95%			93.91%			94.60%			94.35%
EBITDA (loss)	$	452,666		$	250,171		$	1,161,366		$	(3,613)
Normalized EBITDA (loss)	$	502,299		$	275,820		$	1,181,042		$	306,648
Net Income (loss)	$	384,630		$	156,496		$	943,408		$	(312,162)
Basic EPS	$	0.01		$	0.00		$	0.02		$	(0.01)
Diluted EPS	$	0.01		$	0.00		$	0.02		$	(0.01)

	As at
	September 30 2020			June 30 2020			December 31 2019			September 30 2019
Cash	$	2,284,104		$	1,823,200		$	1,570,483		$	1,705,416
Liquidity	$	3,284,104		$	2,823,200		$	1,570,483		$	1,705,416
Working Capital	$	3,122,343		$	2,722,421		$	2,086,700		$	1,845,365

About YANGAROO:

Yangaroo is a software leader in work-flow management for advertising, music, and awards industries. YANGAROO’s patented Digital Media Distribution System is a leading secure business to business cloud-based solution that provides clearance, delivery, and secure API integration for various work-flow challenges in media distribution.

YANGAROO has offices in Toronto, New York, and Los Angeles. YANGAROO trades on the TSX Venture Exchange (TSX-V) under the symbol YOO and in the U.S. under OTCBB: YOOIF.

For YANGAROO Investor Inquiries:
Grant Schuetrumpf
Phone: (416) 534-0607
[email protected]

Cautionary Note Regarding Forward-looking Statements

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes.

Forward-looking statements are subject to both known and unknown risks, uncertainties and other factors, many of which are beyond the control of YANGAROO, that may cause the actual results, level of activity, performance or achievements of YANGAROO to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the use of proceeds of the offering, receipt of all necessary approvals of the offering, general business, economic, competitive, political and social uncertainties; negotiation uncertainties and other risks of the technology industry. Although YANGAROO has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended.

Forward-looking statements are not a guarantee of future performance and involve a number of risks and uncertainties, some of which are described herein. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause YANGAROO’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Any forward-looking statements are made as of the date hereof and, except as required by law, neither YANGAROO assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.